Research programme: diabetic foot ulcer therapy - PLIVA

Drug Profile

Research programme: diabetic foot ulcer therapy - PLIVA

Alternative Names: Diabetic foot ulcer therapy research programme - PLIVA; PLR-15

Latest Information Update: 16 Aug 2007

Price : $50

At a glance

  • Originator PLIVA d.d.
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic foot ulcer

Most Recent Events

  • 20 Jul 2005 Preclinical trials in Diabetic foot ulcer in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top